TrialThe Lancet. Infectious diseases2022

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.

Gary A Herman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.